• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Celestica Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket

    7/27/23 8:06:34 AM ET
    $CING
    $CLS
    $CTCX
    $ENG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Technology
    Get the next $CING alert in real time by email

    Gainers

    • Celestica Inc. (NYSE:CLS) shares surged 42.2% to $23.40 in pre-market trading after the company announced better-than-expected second-quarter results.
    • Carmell Therapeutics Corporation (NASDAQ:CTCX) rose 29.3% to $3.88 in pre-market trading after declining 20% on Wednesday.
    • Mallinckrodt plc (NYSE:MNK) gained 21.4% to $1.53 in pre-market trading. Mallinckrodt shares jumped 186% on Wednesday following a report suggesting the company is considering bankruptcy as part of a plan to avoid opioid payments.
    • ENGlobal Corporation (NASDAQ:ENG) shares gained 19.2% to $0.40 in pre-market trading after declining over 10% on Wednesday.
    • Genesis Unicorn Capital Corp. (NASDAQ:GENQ) shares climbed 16.8% to $11.39 in pre-market trading after falling around 7% on Wednesday.
    • Enovix Corporation (NASDAQ:ENVX) shares gained 14.5% to $22.44 in pre-market trading following a narrower-than-expected quarterly loss.
    • Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) gained 13.8% to $4.46 in pre-market trading. LIXTE Biotechnology recently announced closing of $3.5 million registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.
    • Cingulate Inc. (NASDAQ:CING) rose 12.4% to $0.6885 in pre-market trading.
    • Helix Energy Solutions Group, Inc. (NYSE:HLX) shares rose 10.5% to $9.55 in pre-market trading after the company reported better-than-expected second-quarter results.
    • Meta Platforms, Inc. (NASDAQ:META) shares rose 8.5% to $324.00 in pre-market trading after the company reported better-than-expected second-quarter financial results.

    Losers

    • Yellow Corporation (NASDAQ:YELL) fell 24% to $0.7750 in pre-market trading. Yellow is preparing to file for bankruptcy, according to the Wall Street Journal.
    • TPI Composites, Inc. (NASDAQ:TPIC) fell 20.3% to $8.49 in pre-market trading after the company lowered its 2023 forecast.
    • National Vision Holdings, Inc. (NASDAQ:EYE) fell 19.3% to $19.99 in pre-market trading. National Vision Holdings said its partnership with Walmart Inc. will be ending in 2024.
    • LendingClub Corporation (NYSE:LC) fell 16.1% to $8.50 in pre-market trading after reporting second-quarter results.
    • Oceaneering International, Inc. (NYSE:OII) shares fell 15.9% to $19.88 in pre-market trading following weaker-than-expected quarterly results.
    • Impinj, Inc. (NASDAQ:PI) shares fell 14.7% to $67.00 in pre-market trading after reporting quarterly results.
    • MaxLinear, Inc. (NYSE:MXL) fell 10.5% to $26.51 in pre-market after the company posted downbeat second-quarter sales and issued weak sales guidance.
    • Silicon Motion Technology Corporation (NASDAQ:SIMO) shares fell 9.8% to $58.95 in pre-market trading after jumping 25% on Wednesday.
    • POSCO Holdings Inc. (NYSE:PKX) fell 9.6% to $115.50 in pre-market trading. POSCO Holdings recently reported quarterly financial results.
    • Tango Therapeutics, Inc. (NASDAQ:TNGX) fell 8.8% to $2.71 in pre-market trading. Tango Therapeutics recently said that the first patient has been dosed in the Phase 1/2 trial of TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.

     

    Now Read This: Investor Sentiment Declines After Fed Raises Interest Rates By 0.25%

    Get the next $CING alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING
    $CLS
    $CTCX
    $ENG

    CompanyDatePrice TargetRatingAnalyst
    Meta Platforms Inc.
    $META
    3/5/2026Buy → Neutral
    Arete
    Meta Platforms Inc.
    $META
    3/5/2026Hold → Buy
    Erste Group
    Oceaneering International Inc.
    $OII
    3/3/2026$28.00 → $34.00Hold
    TD Cowen
    Enovix Corporation
    $ENVX
    2/26/2026$15.00 → $7.50Hold
    TD Cowen
    Meta Platforms Inc.
    $META
    2/23/2026$849.00 → $856.00Overweight
    Wells Fargo
    Tango Therapeutics Inc.
    $TNGX
    2/23/2026$19.00Outperform
    Mizuho
    Impinj Inc.
    $PI
    2/6/2026$112.00Outperform → In-line
    Evercore ISI
    Meta Platforms Inc.
    $META
    1/29/2026$770.00 → $800.00Overweight
    Barclays
    More analyst ratings

    $CING
    $CLS
    $CTCX
    $ENG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $CLS
    $CTCX
    $ENG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Chakravarthy Arthi covered exercise/tax liability with 894 shares, decreasing direct ownership by 0.20% to 457,203 units (SEC Form 4)

    4 - Enovix Corp (0001828318) (Issuer)

    3/10/26 7:07:17 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 4 filed by Enovix Corporation

    4 - Enovix Corp (0001828318) (Issuer)

    3/10/26 7:07:33 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    SEC Form 4 filed by CEO Sanborn Scott

    4 - LendingClub Corp (0001409970) (Issuer)

    3/9/26 8:32:32 PM ET
    $LC
    Finance: Consumer Services
    Finance

    $CING
    $CLS
    $CTCX
    $ENG
    SEC Filings

    View All

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    3/10/26 4:00:37 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by MaxLinear Inc.

    144 - MAXLINEAR, INC (0001288469) (Subject)

    3/6/26 5:59:23 PM ET
    $MXL
    Semiconductors
    Technology

    SEC Form 144 filed by National Vision Holdings Inc.

    144 - National Vision Holdings, Inc. (0001710155) (Subject)

    3/6/26 4:35:25 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $CING
    $CLS
    $CTCX
    $ENG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Meta Platforms downgraded by Arete

    Arete downgraded Meta Platforms from Buy to Neutral

    3/5/26 8:27:42 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    Meta Platforms upgraded by Erste Group

    Erste Group upgraded Meta Platforms from Hold to Buy

    3/5/26 8:23:30 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    TD Cowen reiterated coverage on Oceaneering Intl with a new price target

    TD Cowen reiterated coverage of Oceaneering Intl with a rating of Hold and set a new price target of $34.00 from $28.00 previously

    3/3/26 8:00:37 AM ET
    $OII
    Oilfield Services/Equipment
    Energy

    $CING
    $CLS
    $CTCX
    $ENG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MaxLinear, Inc. Announces Upcoming Financial Conference Participation

    MaxLinear, Inc. (NASDAQ:MXL), a leading provider of radio frequency (RF), analog, digital and mixed-signal integrated circuits, today announced that it will participate in the following upcoming financial conferences: Cantor Tech and Industrial Growth Conference in New York City on March 11th at 9:20 am ET. A webcast of the session will be available at https://investors.maxlinear.com. 38th Annual Roth Capital Conference in Dana Point, Calif. on March 23rd. About MaxLinear, Inc. MaxLinear, Inc. (NASDAQ:MXL) is a leading provider of radio frequency (RF), analog, digital and mixed-signal integrated circuits for access and connectivity, wired and wireless infrastructure, and industr

    3/9/26 4:35:00 PM ET
    $MXL
    Semiconductors
    Technology

    Powell Max Limited Successfully Repositions for Its Next Phase of Growth

    Hong Kong, TX, March 09, 2026 (GLOBE NEWSWIRE) -- Powell Max Limited (NASDAQ:PMAX) ("Powell Max" or the "Company"), a financial communications services provider, is pleased to provide the following corporate update regarding its successful repositioning. Key Highlights: Raised $17 million in capital from new investorsAppointed new Chairman and Chief Executive Officer Geordan PursgloveReconstituted the Board of DirectorsRegained compliance with Nasdaq listing requirements Powell Max Chairman and Chief Executive Officer Geordan Pursglove commented, "My first month at Powell Max has been extremely productive. We successfully completed a corporate restructuring in a short timeframe, raised

    3/9/26 8:30:00 AM ET
    $ALBT
    $CISO
    $GRDX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Professional Services
    Consumer Discretionary

    Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $

    3/6/26 5:33:52 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    $CLS
    $CTCX
    $ENG
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    $CING
    $CLS
    $CTCX
    $ENG
    Financials

    Live finance-specific insights

    View All

    National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial Results

    2025 Results Mark a Year of Strong Momentum Fueled by Strategic Transformation, Cost Discipline Expansion Into Targeted Customer Cohorts Drove Enhanced Profitability, Positioning Company for Sustained Growth Provides 2026 Guidance Fourth quarter 2025 highlights compared to fourth quarter 2024*: Net revenue from continuing operations of $503.4 million, increased 15.1% Comparable store sales growth of 6.6% and Adjusted Comparable Store Sales Growth of 4.8%, represented 12 consecutive quarters of positive growth Net income from continuing operations of $3.3 million, Diluted EPS from continuing operations of $0.04, with Income (loss) from continuing operations margin improving to 0.7

    3/4/26 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Helix Reports Fourth Quarter and Full Year 2025 Results

    Helix Energy Solutions Group, Inc. ("Helix") (NYSE:HLX) reported net income of $8.3 million, or $0.06 per diluted share, for the fourth quarter 2025 compared to net income of $22.1 million, or $0.15 per diluted share, for the third quarter 2025 and net income of $20.1 million, or $0.13 per diluted share, for the fourth quarter 2024. Net income during the fourth quarter 2025 included a non-cash impairment charge for certain of our oil and gas properties of approximately $18.1 million (pre-tax). Helix reported Adjusted EBITDA1 of $73.9 million for the fourth quarter 2025 compared to $103.7 million for the third quarter 2025 and $71.6 million for the fourth quarter 2024. For the full year 20

    2/23/26 6:15:00 PM ET
    $HLX
    Oilfield Services/Equipment
    Energy

    Oceaneering Reports Fourth Quarter and Full Year 2025 Results

    Oceaneering International, Inc. ("Oceaneering") (NYSE:OII) today reported fourth quarter and full year 2025 results. Fourth Quarter 2025 Results As compared to the fourth quarter of 2024: Revenue was $669 million, a decrease of 6%. Operating income was $65.4 million, a decrease of 16%. Net income was $178 million, an increase of 217%, which included a discrete tax benefit due to the release of valuation allowances for deferred tax assets. Adjusted EBITDA was $90.5 million, a decrease of 11%. Cash Flow and Share Repurchases Cash flow provided by operating activities was $221 million. Free cash flow was $191 million. Shares repurchased were 419,005 for approximat

    2/18/26 5:01:00 PM ET
    $OII
    Oilfield Services/Equipment
    Energy

    $CING
    $CLS
    $CTCX
    $ENG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by TPI Composites Inc.

    SC 13G/A - TPI COMPOSITES, INC (0001455684) (Subject)

    11/14/24 7:49:51 PM ET
    $TPIC
    Industrial Machinery/Components
    Industrials